Condition: Refractory Solid Tumors · Relapsed Solid Tumors · Relapsed Neuroblastoma · Sponsor: Theodore Laetsch
The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agent (phase 1A) and in combination with vincristine and temozolomide (phase 1B). The phase 2 primary objective is to estimate the objective response rate (ORR) in children with refractory, progressive and relapsed NBL and rhabdomyosarcoma (RMS) treated with the RP2D of PEEL-224 in combination with vincristine and temozolomide.
This description comes directly from the study's public registry record.
Meghan Donnelly, MPH · 267-426-9343 · donnellymt@chop.edu
James Robinson, MSW, MPH · 215-590-2053 · robinsonj9@chop.edu
Always discuss trial participation with your own doctor first.
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| Boston Children's Hospital | Boston, Massachusetts, United States | Not Yet Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Not Yet Recruiting |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| Texas Children's Hospital | Houston, Texas, United States | Recruiting |
| University of Utah Hospital | Salt Lake City, Utah, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06721689